Alkermes Plc Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Alkermes (ALKS) PT Lowered to $47 at Credit Suisse
October 24, 2018 8:54 AM EDTCredit Suisse analyst Vamil Divan lowered the price target on Alkermes (NASDAQ: ALKS) to $47.00 (from $51.00) while maintaining an Outperform rating following Q3.
Divan modestly reduces their sales estimates for Vivitrol and Aristada and also increase some of their expense assumptions... More
Alkermes (ALKS) Tops Q3 EPS by 15c, Revenues Beat; Raises FY18 EPS Guidance
October 23, 2018 7:05 AM EDTAlkermes (NASDAQ: ALKS) reported Q3 EPS of $0.07, $0.15 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $248.7 million versus the consensus estimate of $236.7 million.
"Our solid results in the quarter were in-line with expectations, driven by the growth of our proprietary commercial products, the continued strength of our royalty and manufacturing business, and the important investments we are making in our late-stage pipeline and commercial... More
